Neonatal Hyperbilirubinemia: A Case of Complex Management Involving ABO Incompatibility, Sepsis, and Suspected G6PD Deficiency treated with Methyl Prednisolone.
Main Article Content
Keywords
Hyperbilirubinemia, Management, Methylprednisolone, Neonatal Jaundice
Abstract
Newborn jaundice (NNJ), especially due to ABO incompatibility, is a major global health concern. Phototherapy is standard treatment, with exchange transfusions reserved for severe cases. However, in some babies these therapies may be ineffective, requiring additional immunomodulatory treatments. Limited access to these treatments in developing countries creates a critical gap, worsening jaundice severity. A 22-hour old term neonate presented with rapidly progressive severe neonatal hyperbilirubinemia (NNJ) within 15 hours of life, consistent with ABO incompatibility based on discordant maternal and infant’s blood types (mother: O, baby: B-positive). Despite aggressive initial management with phototherapy and exchange transfusions, the NNJ exhibited limited improvement. Sepsis and G6PD deficiency were considered as potential contributing factors, although confirmatory testing for G6PD deficiency was deferred due to unavailability of the diagnostic test in our setting. Given a sibling's documented successful response to methylprednisolone for a similar presentation, a brief course of low-dose intravenous methylprednisolone (1mg/kg/day in 2 divided doses) (off-label use) was cautiously initiated. This resulted in a rapid and significant improvement in the neonate's hyperbilirubinemia. Methylprednisolone was prescribed for 3 days after which it was discontinued. Following close observation for 3 days and confirmation of no neurological sequelae, the neonate was discharged home in stable condition. Managing severe, worsening NNJ, especially with multiple aetiologies, is complex. Standard therapies may be inadequate. While promising, immunomodulatory therapies like IVIG may be limited in resource-poor settings. Methylprednisolone shows potential but lacks strong clinical evidence. Well-designed studies are essential to explore its safety and efficacy, particularly in developing countries with limited treatment options.
References
2. Bhutani VK, Johnson LH. Neonatal Hyperbilirubinemia. When to Screen Obstet Gynecol 2005;491–502.
3. Shabo SK, Gargary KH, Erdeve O. Indirect Neonatal Hyperbilirubinemia and the Role of Fenofibrate as an Adjuvant to Phototherapy. Children 2023;10(7):1–9.
4. Saloojee H. Innovative approaches to neonatal jaundice diagnosis and management in low-resourced settings. South African Fam Pract 2024;66(1):1–5.
5. Martin S, Jerome RN, Epelbaum MI, Williams AM, Walsh W. Addressing hemolysis in an infant due to mother-infant ABO blood incompatibility. J Med Libr Assoc 2008;96(3):183–8.
6. Routray SS, Mishra D, Kanungo GN, Behera R. Hemolytic Disease of Newborn due to ABO Incompatibility between B Blood Group Mother and A Blood Group Neonate. J Lab Physicians 2023;15(01):146–8.
7. Stanley I, Chung M, Kulig J, O’Brien R, Sege R, Glicken S, et al. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 2004;114(1).
8. Kemper AR, Newman TB, Slaughter JL, Maisels MJ, Watchko JF, Downs SM, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2022;150(3).
9. Dey SK, Afroze S, Jahan I, Mannan M, Shahidullah M. Neonatal Hyperbilirubinemia associated with Minor Blood Group Incompatibility: Two Case Reports. Bangladesh J Child Heal 2017;41(1):64–6.
10. Jajoo M, Mittal M, Dabas V. Rare case of bilirubin encephalopathy due to neonatal lupus erythematosus. J Clin Neonatol 2016;5(2):134.
11. Erin ES, Neera KG. Jaundice and hyperbilirubinemia in the newborn. In: Nelson Textbook of Pediatrics. 21st edition Karen M Wilson, editor. Elsevier; (2019) page 68–77.
12. Lieberman L, Spradbrow J, Keir A, Dunn M, Lin Y, Callum J. Use of intravenous immunoglobulin in neonates at a tertiary academic hospital: a retrospective 11-year study. Transfusion 2016;56(11):2704–11.
13. Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. 2020.
14. Ocejo A, Ricardo C. Methylprednisolone. StatPearls 2024;
15. Ohkubo H, Okuda K. Effects of Corticosteroids on Bilirubin Metabolism in Patients with Gilbert ’ s Syndrome. 1981;1(2):168–72.
16. Setyoboedi B, Utomo MT, Prihaningtyas RA, Arief S. Effectiveness of oral methylprednisolone as adjuvant therapy for clinical improvement, biochemical markers, and inflammation in infants with cholestasis. Heliyon 2024;10(14):e34110. https://doi.org/10.1016/j.heliyon.2024.e34110